A public health task force is evaluating a new rapid serologic assay for a tick-borne illness endemic to a specific region. During initial clinical validation at a tertiary care center, the assay was tested on a cohort of individuals, exactly half of whom had PCR-confirmed infection. In this validation cohort, the assay correctly identified of the infected individuals and yielded a positive result in of the uninfected individuals.
The task force now plans to deploy this assay to a rural outpatient clinic where epidemiological data indicates that of the tested patients actually have the infection.
If a patient at this rural clinic tests positive using the rapid assay, what is the probability (expressed as a percentage) that they truly have the infection?
Answer: 80 %